Cardio Diagnostics Holdings Inc (CDIO)

[Whalatane]

CHICAGO, January 02, 2024--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced that the American Medical Association (AMA) has assigned a dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analysis (PLA), 0440U, for the company’s AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. Receipt of this new CPT PLA code, which will be effective on April 1, 2024, is a significant step toward payer billing and payment, facilitating broader adoption of the first and only integrated genetic-epigenetic diagnostic blood test for CHD.

Congrats on the move.
Doubt if payers or patients will pay the $350 ? the Co wants for this test ...but so far the mkt's buying the hype
No position
Good luck
Kiwi